These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 18006849)

  • 1. Chimeric NKG2D modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways.
    Zhang T; Barber A; Sentman CL
    Cancer Res; 2007 Nov; 67(22):11029-36. PubMed ID: 18006849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor.
    Zhang T; Barber A; Sentman CL
    Cancer Res; 2006 Jun; 66(11):5927-33. PubMed ID: 16740733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer.
    Barber A; Zhang T; DeMars LR; Conejo-Garcia J; Roby KF; Sentman CL
    Cancer Res; 2007 May; 67(10):5003-8. PubMed ID: 17510432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners.
    Radaeva S; Sun R; Jaruga B; Nguyen VT; Tian Z; Gao B
    Gastroenterology; 2006 Feb; 130(2):435-52. PubMed ID: 16472598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.
    Ghiringhelli F; Ménard C; Terme M; Flament C; Taieb J; Chaput N; Puig PE; Novault S; Escudier B; Vivier E; Lecesne A; Robert C; Blay JY; Bernard J; Caillat-Zucman S; Freitas A; Tursz T; Wagner-Ballon O; Capron C; Vainchencker W; Martin F; Zitvogel L
    J Exp Med; 2005 Oct; 202(8):1075-85. PubMed ID: 16230475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fas-ligand-mediated paracrine T cell regulation by the receptor NKG2D in tumor immunity.
    Groh V; Smythe K; Dai Z; Spies T
    Nat Immunol; 2006 Jul; 7(7):755-62. PubMed ID: 16732291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-12 improves cytotoxicity of natural killer cells via upregulated expression of NKG2D.
    Zhang C; Zhang J; Niu J; Zhou Z; Zhang J; Tian Z
    Hum Immunol; 2008 Aug; 69(8):490-500. PubMed ID: 18619507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NKG2D function protects the host from tumor initiation.
    Smyth MJ; Swann J; Cretney E; Zerafa N; Yokoyama WM; Hayakawa Y
    J Exp Med; 2005 Sep; 202(5):583-8. PubMed ID: 16129707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ex vivo expansion of non-MHC-restricted cytotoxic effector cells as adoptive immunotherapy for myeloma.
    Wu JY; Ernstoff MS; Hill JM; Cole B; Meehan KR
    Cytotherapy; 2006; 8(2):141-8. PubMed ID: 16698687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy with chimeric NKG2D receptors leads to long-term tumor-free survival and development of host antitumor immunity in murine ovarian cancer.
    Barber A; Zhang T; Sentman CL
    J Immunol; 2008 Jan; 180(1):72-8. PubMed ID: 18097006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy.
    Zhang T; Lemoi BA; Sentman CL
    Blood; 2005 Sep; 106(5):1544-51. PubMed ID: 15890688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blockade of NKG2D signaling prevents the development of murine CD4+ T cell-mediated colitis.
    Ito Y; Kanai T; Totsuka T; Okamoto R; Tsuchiya K; Nemoto Y; Yoshioka A; Tomita T; Nagaishi T; Sakamoto N; Sakanishi T; Okumura K; Yagita H; Watanabe M
    Am J Physiol Gastrointest Liver Physiol; 2008 Jan; 294(1):G199-207. PubMed ID: 17962357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-15 mediates protection against experimental tuberculosis: a role for NKG2D-dependent effector mechanisms of CD8+ T cells.
    Rausch A; Hessmann M; Hölscher A; Schreiber T; Bulfone-Paus S; Ehlers S; Hölscher C
    Eur J Immunol; 2006 May; 36(5):1156-67. PubMed ID: 16619285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric NKG2D T cells require both T cell- and host-derived cytokine secretion and perforin expression to increase tumor antigen presentation and systemic immunity.
    Barber A; Sentman CL
    J Immunol; 2009 Aug; 183(4):2365-72. PubMed ID: 19625653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells.
    Barber A; Meehan KR; Sentman CL
    Gene Ther; 2011 May; 18(5):509-16. PubMed ID: 21209626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors.
    Spear P; Barber A; Rynda-Apple A; Sentman CL
    Immunol Cell Biol; 2013 Jul; 91(6):435-40. PubMed ID: 23628805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin.
    Hayakawa Y; Kelly JM; Westwood JA; Darcy PK; Diefenbach A; Raulet D; Smyth MJ
    J Immunol; 2002 Nov; 169(10):5377-81. PubMed ID: 12421908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional analysis of Ran/TC4 as a protein regulating T-cell costimulation.
    Nieland JD; Haks MC; Kremers BL; Leupers TJ; Bakker AQ; Offringa R; Kruisbeek AM
    Cancer Gene Ther; 1998; 5(5):259-73. PubMed ID: 9824045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetically targeted T cells eradicate established breast cancer in syngeneic mice.
    Wang H; Wei H; Zhang R; Hou S; Li B; Qian W; Zhang D; Kou G; Dai J; Guo Y
    Clin Cancer Res; 2009 Feb; 15(3):943-50. PubMed ID: 19188165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration.
    Bracci L; Moschella F; Sestili P; La Sorsa V; Valentini M; Canini I; Baccarini S; Maccari S; Ramoni C; Belardelli F; Proietti E
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):644-53. PubMed ID: 17255288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.